Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

ReNeuron Group (AIM: RENE)

Last close As at 21/11/2024

3.38

— 0.00 (0.00%)

Market capitalisation

2m

ReNeuron is a UK biotech company developing allogeneic cell therapies. The first pivotal Phase IIb trial for CTX neural stem cells for chronic stroke disability is underway. Human retinal progenitor cells (hRPCs) are also being studied for RP (in Phase I/IIa).

Latest Insights

View More

Healthcare | Update

ReNeuron Group — H124 results reaffirm focus on CustomEX

Healthcare | Flash note

ReNeuron Group — A step forward on the Exosome delivery platform

Healthcare | Update

ReNeuron Group — Full steam ahead with CustomEx

Flash note

ReNeuron Group — Encouraging data for iPSCs opens potential
ReNeuron-Group_resized
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 0.0 (20.6) (69.3)
Relative (0.6) (22.5) (68.1)
52 week high/low 10.8p/3.4p

Financials

Edison Investment Research is terminating coverage on ReNeuron Group (RENE). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Mar Revenue (£m) EBITDA (£m) PBT (£m) EPS (fd) (p) P/E (x) P/CF (x)
2022A 0.4 N/A (11.1) (17.01) N/A N/A
2023A 0.5 N/A (6.7) (9.47) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Research

ReNeuron-Group_resized

Flash note

Healthcare

ReNeuron Group — A step forward on the Exosome delivery platform

Update

Healthcare

ReNeuron Group — Full steam ahead with CustomEx
ReNeuron-Group_resized

Healthcare

Update

ReNeuron Group — H124 results reaffirm focus on CustomEX

ReNeuron-Group_resized
View All

Further insights

insight

Healthcare

Stem cells

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free